Publications by authors named "Robert Fogel"

Claim this Profile
O
Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial.
David J Jackson, Njira L Lugogo, Mark Gurnell, Liam G Heaney, Stephanie Korn, Robert Fogel

Lancet Respir Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH).
Robert A Wood, R Sharon Chinthrajah, Amanda K Rudman Spergel, Denise C Babineau, Scott H Sicherer, Robert B Fogel

J Allergy Clin Immunol Glob· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians.
Jing Li, Jing Yang, Lingfei Kong, Yijiang Huang, Ping Chen, Robert Fogel

Asian Pac J Allergy Immunol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
Weiru Yuan, Shuling Hu, Min Li, Lijia Yang, Lingling Liu, Robert Fogel

Dermatol Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
Dave Singh, Jim M Wild, Dinesh Saralaya, Rod Lawson, Helen Marshall, Robert Fogel

Respir Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database.
Konstantinos Kostikas, David Price, Florian S Gutzwiller, Bethan Jones, Emil Loefroth, Robert Fogel

Int J Chron Obstruct Pulmon Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a analysis of a randomised phase III study.
Jing Li, Changzheng Wang, Chuntao Liu, Jian Kang, Lingfei Kong, Robert Fogel

World Allergy Organ J· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Add-On Omalizumab for Inadequately Controlled Severe Pollinosis Despite Standard-of-Care: A Randomized Study.
Kimihiro Okubo, Mitsuhiro Okano, Norio Sato, Yuko Tamaki, Hiromi Suzuki, Robert Fogel

J Allergy Clin Immunol Pract· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study.
Konstantinos Kostikas, Chin Kook Rhee, John R Hurst, Piergiuseppe Agostoni, Hui Cao, Robert Fogel

Pragmat Obs Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort.
Jennifer A Namazy, Lucie Blais, Elizabeth B Andrews, Angela E Scheuerle, Michael D Cabana, Robert B Fogel

J Allergy Clin Immunol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population.
Jørgen Vestbo, Claus F Vogelmeier, Mark Small, James Siddall, Robert Fogel

Int J Chron Obstruct Pulmon Dis· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in COPD Exacerbation Risk Between Women and Men: Analysis From the UK Clinical Practice Research Datalink Data.
Daiana Stolz, Konstantinos Kostikas, Emil Loefroth, Robert Fogel, Florian S Gutzwiller

Chest· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study.
David B Price, Jaco Voorham, Guy Brusselle, Andreas Clemens, Konstantinos Kostikas, Robert Fogel

NPJ Prim Care Respir Med· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of exacerbations and blood eosinophils in UK and US COPD populations.
Claus F Vogelmeier, Konstantinos Kostikas, Juanzhi Fang, Hengfeng Tian, Bethan Jones, Robert Fogel

Respir Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion.
Kenneth R Chapman, John R Hurst, Robert B Fogel, Pascal Pfister, Konstantinos Kostikas

Am J Respir Crit Care Med· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
Stefan M Frent, Kenneth R Chapman, Michael Larbig, Alexander Mackay, Robert Fogel

Am J Respir Crit Care Med· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
Jadwiga A Wedzicha, Dave Singh, Ioanna Tsiligianni, Christine Jenkins, Sebastian Fucile, Robert Fogel

Respir Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
Claus F Vogelmeier, Kenneth R Chapman, Marc Miravitlles, Nicolas Roche, Jørgen Vestbo, Robert Fogel

Int J Chron Obstruct Pulmon Dis· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
Timm Greulich, Konstantinos Kostikas, Mina Gaga, Maryam Aalamian-Mattheis, Nadine S Lossi, Robert Fogel

Int J Chron Obstruct Pulmon Dis· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis.
Georgios Ntritsos, Jacob Franek, Lazaros Belbasis, Maria A Christou, Georgios Markozannes, Robert Fogel

Int J Chron Obstruct Pulmon Dis· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Kenneth R Chapman, John R Hurst, Stefan-Marian Frent, Michael Larbig, Robert Fogel

Am J Respir Crit Care Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
Antonio R Anzueto, Konstantinos Kostikas, Karen Mezzi, Steven Shen, Michael Larbig, Robert Fogel

Respir Res· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease.
Nicolas Roche, Kenneth R Chapman, Claus F Vogelmeier, Felix J F Herth, Chau Thach, Robert Fogel

Am J Respir Crit Care Med· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease.
James F Donohue, Paul W Jones, Christian Bartels, Jessica Marvel, Peter D'Andrea, Robert Fogel

Pulm Pharmacol Ther· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.
Konstantinos Kostikas, Maryam Aalamian-Mattheis, Veronica Anna Pagano, Xavier Nunez, Robert Fogel

COPD· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis